For best results when printing this announcement, please click on the linkbelow:
  http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130508:nPnLA09790
 Use of SpHb Noninvasive Hemoglobin Is Part of Leading Medical TeachingFacility's Standardization to Masimo SET Pulse OximetryBURSA, Turkey and  IRVINE, Calif.,  May 8, 2013  /PRNewswire/ -- Masimo (NASDAQ: MASI) and Uludag University Hospital, one of the top educationalhealthcare facilities in all of  Turkey, announce that Uludag has added MasimoSpHb - a breakthrough technology that allows clinicians to noninvasively andcontinuously monitor hemoglobin blood levels.The use of SpHb is part of Uludag's standardization to Masimo SET Measure-Through Motion and Low Perfusion pulse oximetry, clinically shown tovirtually eliminate false alarms1  and help clinicians better detectlife-threatening events.2  This conversion represents Masimo's largestwhole-house technology installation in  Turkey  to date.Uludag University Hospital, with 880 beds and only one of two hospitals in thecountry to have Joint Commission International accreditation, is now leveragingMasimo SpHb in its operating rooms. SpHb has been clinically shown to reducerisky and unnecessary blood transfusions and speeds time to transfuse whenindicated, while dramatically reducing costs.3"We use the Masimo Radical-7 Pulse CO-Oximeter with SpHb primarily for complexneurosurgeries of pediatric patients such as brain tumors and craniosynostosis,"said Dr.  Gulsen Korfali, a professor and Chairman of Anesthesiology andReanimation at Uludag University. "We have a particular need to track hemoglobinlevels on a continuous basis and stay noninvasive on the most vulnerable patientpopulation - children."  "Masimo SET also has tremendously reduced our sensor consumption because theylast longer," Dr. Korfali added. "We used to discard sensors every day. Now wecan use a sensor for up to five days. We also have almost no false alarms and ahigher ability to detect desaturations with Masimo SET in our critical careareas."Hemoglobin levels are used as a primary indicator for red blood cell (RBC)transfusion, but conventional laboratory measurements are only availableintermittently and results can be delayed in the period between blood draw andlaboratory analysis. This time gap of information can lead to sub-optimaltransfusion decisions.4 RBC transfusion overuse as well as delayed RBCtransfusion can increase patient risk and cost of care. Multiple observationalstudies have shown that patients receiving RBC transfusions have an 88% highermortality, 69% higher infection rate, and 250% higher rate of acute respiratorydistress syndrome.5SpHb monitoring provides real-time directional trends in hemoglobin, such asindicating stable hemoglobin when it may be perceived to be dropping, and risinghemoglobin when it may be perceived to not be rising fast enough. A recent studyfrom  Cairo  University in  Egypt  also showed that once clinicians determined atransfusion was needed, they were able to initiate transfusions 82% faster - inabout 9 minutes, compared to about 50 minutes for patients not being monitoredby SpHb.3 That same study also showed SpHb can help clinicians reduceunnecessary and risky RBC transfusions, which can improve patient outcomes whiledramatically lowering the cost of care.Joe Kiani, founder and CEO of Masimo, stated: "We are honored that UludagUniversity Hospital, one of the top-performing hospitals in  Turkey  with aninspiring reputation for excellence, has selected Masimo for its patientmonitoring needs. As a forward-thinking healthcare organization that embracesinnovative medical technologies, we are eager to help Uludag improve its alreadysuperb patient safety and outcomes."1 Shah N, Ragaswamy H, Govindugari K, Estanol L. "Performance of threenew-generation pulse oximeters during motion and low perfusion in volunteers." Journal of Clinical Anesthesia. 2012 (10.1016/j.jclinane.2011.10.012) Availableonline  here2 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T."Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care UnitTransfers: A Before-and-After Concurrence Study."  Anesthesiology,  February2010, Vol. 112, Issue 2. Available online  here3 Awada W.F.N., Maher F. Reduction in Red Blood Cell Transfusions duringNeurosurgery with Noninvasive and Continuous Hemoglobin Monitoring. Proceedingsof the Society for Technology in Anesthesia Annual Meeting ; 2013  Jan 9-12; Phoenix AZ.  Available  here.4 Friedman MT et al. Arch Pathol Lab Med. 2006 Apr;130(4):474-9.5 Marik PE.et.al. Crit Care Med. 2008;36(9):2667-74About Uludag University HospitalUludag University Hospital, with 880 beds and only one of two hospitals in Turkey  to have Joint Commission International accreditation, is now leveragingMasimo SpHb in its operating rooms and Intensive Care Units. Please visit 
  http://en.uludag.edu.tr/
 About MasimoMasimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoringtechnologies that significantly improve patient care-helping solve "unsolvable"problems. In 1995, the company debuted Measure-Through Motion and Low Perfusionpulse oximetry, known as Masimo SET, which virtually eliminated false alarmsand increased pulse oximetry's ability to help clinicians detectlife-threatening events. More than 100 independent and objective studies haveshown that Masimo SET  outperforms other pulse oximetry technologies, evenunder the most challenging clinical conditions, including patient motion and lowperipheral perfusion. In 2005, Masimo introduced rainbow   Pulse CO-Oximetrytechnology, allowing noninvasive and continuous monitoring of blood constituentsthat previously required invasive procedures; total hemoglobin (SpHb), oxygencontent (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), PVI, andperfusion index (PI), in addition to measure-through motion SpO2, and pulserate. In 2008, Masimo introduced Patient SafetyNet, a remote monitoring andwireless clinician notification system designed to help hospitals avoidpreventable deaths and injuries associated with failure to rescue events. In2009, Masimo introduced rainbow  Acoustic Monitoring, the first-evercommercially available noninvasive and continuous monitoring of acousticrespiration rate (RRa). Masimo SET  and Masimo rainbow  technologies also canbe found in over 100 multiparameter patient monitors from over 50 medical devicemanufacturers around the world. Founded in 1989, Masimo has the mission of"Improving Patient Outcome and Reducing Cost of Care  by Taking NoninvasiveMonitoring to New Sites and Applications." Additional information about Masimoand its products may be found at  
  www.masimo.com.
 Forward-Looking StatementsThis press release includes forward-looking statements as defined in Section 27Aof the Securities Act of 1933 and Section 21E of the Securities Exchange Act of1934, in connection with the Private Securities Litigation Reform Act of 1995.These forward-looking statements are based on current expectations about futureevents affecting us and are subject to risks and uncertainties, all of which aredifficult to predict and many of which are beyond our control and could causeour actual results to differ materially and adversely from those expressed inour forward-looking statements as a result of various risk factors, including,but not limited to: risks related to our assumptions regarding the repeatabilityof clinical results; risks related to our belief that Masimo SET has been shownto virtually eliminate false alarms and help clinicians better detectlife-threatening events; risks related to our belief that Masimo's uniquenoninvasive SpHb measurement allows clinicians to noninvasively and continuouslymonitor hemoglobin blood levels, reduces risky and unnecessary bloodtransfusions, speeds necessary blood transfusions, dramatically reduces costs,and contributes to positive clinical outcomes and patient safety in all patientsand in every clinical situation; as well as other factors discussed in the "RiskFactors" section of our most recent reports filed with the Securities andExchange Commission ("SEC"), which may be obtained for free at the SEC's websiteat  
  www.sec.gov.
  Although we believe that the expectations reflected in ourforward-looking statements are reasonable, we do not know whether ourexpectations will prove correct. All forward-looking statements included in thispress release are expressly qualified in the
ir entirety by the foregoingcautionary statements. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of today's date. We do notundertake any obligation to update, amend or clarify these statements or the"Risk Factors" contained in our most recent reports filed with the SEC, whetheras a result of new information, future events or otherwise, except as may berequired under the applicable securities laws.   Media Contacts:                                            Prof. Dr. Gulsen Korfali    Mike Drummond                  Uludag University Hospital  Masimo Corporation             Phone: +90 5337460092       Phone: (949) 297-7434          Email:  sen@Uludag.edu.tr   Email:  mdrummond@masimo.com    Masimo, SET, Signal Extraction Technology, Improving Patient Outcome andReducing Cost of Care... by Taking Noninvasive Monitoring to New Sites andApplications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow AcousticMonitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, PulseCO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registeredtrademarks of Masimo Corporation. The use of the trademarks Patient SafetyNetand PSN is under license from University HealthSystem Consortium.SOURCE  Masimo